COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA
Author(s)
Jazmin Pinzon, Jr., Epidemiologist physcians, health economics;
AbbVie, Epidemiologist, BOGOTÁ, D.C., Colombia
AbbVie, Epidemiologist, BOGOTÁ, D.C., Colombia
OBJECTIVES: To evaluate the clinical and economic impact of upadacitinib (15 mg and 30 mg) compared with dupilumab, abrocitinib, baricitinib, and lebrikizumab in Colombia
METHODS: Methods: A cost-consequence model based on a decision tree was developed from the perspective of the Colombian health system over a one-year time horizon. The model included direct medical costs of drugs, administration, adverse events, and subsequent treatments. Clinical outcomes were derived from pivotal trials, considering EASI75 (16 weeks) and EASI90 (52 weeks) response rates.
RESULTS: In the base scenario, increasing the market share of upadacitinib (15 mg + 30 mg) led to a 10.7% improvement in clinical response (17,584 additional responders) and a 9.1% reduction in adverse events (20,018 fewer cases). Treatment costs rose by COP $119.5 billion, partly offset by COP $2.1 billion savings in adverse events, resulting in a net cost increase of 4.9%. An alternative scenario including lebrikizumab yielded a smaller clinical benefit (+7.8%) but improved safety and a lower budget impact (+3.3%)
CONCLUSIONS: Increasing upadacitinib use in moderate-to-severe AD improves patient outcomes and safety, albeit with higher total costs. Incorporating lebrikizumab may balance clinical and economic outcomes. These findings support price negotiations and patient stratification to enhance efficiency and sustainability in Colombia’s health system.
METHODS: Methods: A cost-consequence model based on a decision tree was developed from the perspective of the Colombian health system over a one-year time horizon. The model included direct medical costs of drugs, administration, adverse events, and subsequent treatments. Clinical outcomes were derived from pivotal trials, considering EASI75 (16 weeks) and EASI90 (52 weeks) response rates.
RESULTS: In the base scenario, increasing the market share of upadacitinib (15 mg + 30 mg) led to a 10.7% improvement in clinical response (17,584 additional responders) and a 9.1% reduction in adverse events (20,018 fewer cases). Treatment costs rose by COP $119.5 billion, partly offset by COP $2.1 billion savings in adverse events, resulting in a net cost increase of 4.9%. An alternative scenario including lebrikizumab yielded a smaller clinical benefit (+7.8%) but improved safety and a lower budget impact (+3.3%)
CONCLUSIONS: Increasing upadacitinib use in moderate-to-severe AD improves patient outcomes and safety, albeit with higher total costs. Incorporating lebrikizumab may balance clinical and economic outcomes. These findings support price negotiations and patient stratification to enhance efficiency and sustainability in Colombia’s health system.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE394
Topic
Economic Evaluation
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)